NRx Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 30.15 million compared to USD 39.75 million a year ago. Basic loss per share from continuing operations was USD 4 compared to USD 6 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | +0.28% | +18.33% | -22.83% |
Apr. 18 | NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq | MT |
Apr. 18 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.83% | 37M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023